David C. Hastings

David C. Hastings

Chief Financial Officer at Arbutus Biopharma Corporation

Are you David C. Hastings? Claim your profile
 
  • IDENTIFY executive and board member connections in David C. Hastings's network.
  • FOLLOW changes in David C. Hastings's employment.
  • CONNECT with David C. Hastings through your network of contacts.

David C. Hastings's Executive Work History


Current
Chief Financial Officer,
Chief Financial Officer
Arbutus Biopharma Corporation DEF 14A on 04/11/2022
Arbutus Biopharma Corporation
Board Member,
Board Member
Entasis Therapeutics Holdings Inc. 10-K/A on 05/02/2022
Entasis Therapeutics Holdings Inc.
Board Member,
Board Member
SCYNEXIS, Inc. DEF 14A on 05/12/2022
SCYNEXIS, Inc.
Board Member,
Board Member
Vascular Biogenics Ltd. 20-F on 03/25/2021
Vascular Biogenics Ltd.
Past
To view David C. Hastings's complete executive work history,
Education
B.A., University Of Vermont
Age
60
 

David C. Hastings's Biography


Mr. Hastings joined Arbutus in June 2018 and serves as the Company’s Chief Financial Officer. Mr. Hastings has more than 25 years of executive finance and operational experience with biotech and pharma companies in various stages of development, including commercial. Mr. Hastings spent the majority of his career at Incyte Corporation where he served as Chief Financial Officer and Executive Vice President. During his tenure, Mr. Hastings oversaw all financial aspects as Incyte transitioned from research and development to commercialization, following the launch of Jakafi® (ruxolitinib). Mr. Hastings also previously served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc., where he played an important role in ArQule's transition into a drug discovery and development organization, and its two strategic acquisitions, including the purchase of Cyclis Pharmaceuticals Inc. Mr. Hastings held prior executive and senior level financial positions at Sepracor, Inc. and Unilife Corporation (a medical device company). Mr. Hastings is a Board member and Chair of the Audit Committees of Scynexis, Inc., VBL Therapeutics and Entasis, Inc. Mr. Hastings received his BA from the University of Vermont.

Source: Arbutus Biopharma Corporation on 08/23/2022

 

By accessing ExecAtlas, you can view bios, network, connections and references of industry leading executives like David C. Hastings. More specifically, you'll be able to:

  • IDENTIFY executive and board member connections in David C. Hastings's network.
  • FOLLOW changes in David C. Hastings's employment.
  • CONNECT with David C. Hastings through your network of contacts.
 

Access over 1,500,000 executive and board member profiles.

Example: David C. Hastings

David C. Hastings's Connections (118)


Ron Cohen M.D.
President and Chief Executive Officer, Acorda Therapeutics, Inc.
Marc D. Kozin
Board Member, UFP Technologies, Inc.
Susan L. Kelley M.D.
Board Member, Dare Bioscience, Inc.
Matt Trudeau
Former Chief Commercial Officer, Vascular Biogenics Ltd.
Paul A. Friedman M.D.
Chairman of the Board and Chief Executive Officer, Madrigal Pharmaceuticals, Inc.
Ann F. Hanham Ph.D.
Chairman, HTG Molecular Diagnostics, Inc.
John C. Ryan
Former President, Chief Executive Officer and Director, Unilife Corporation
James N. Topper M.D., Ph.D.
Chief Executive Officer and Chairman, Frazier Lifesciences Acquisition Corporation
Marco Taglietti M.D.
President, Chief Executive Officer and Director, SCYNEXIS, Inc.
Gaston Picchio Ph.D.
Chief Development Officer, Arbutus Biopharma Corporation